{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T04:41:49Z","timestamp":1766378509300},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T00:00:00Z","timestamp":1488499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00280-017-3261-5","type":"journal-article","created":{"date-parts":[[2017,3,3]],"date-time":"2017-03-03T06:09:21Z","timestamp":1488521361000},"page":"705-710","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease"],"prefix":"10.1007","volume":"79","author":[{"given":"Kosuke","family":"Kashiwabara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Semba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Tsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,3,3]]},"reference":[{"key":"3261_CR1","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947\u2013957","journal-title":"N Engl J Med"},{"key":"3261_CR2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y et al West Japan Oncology Group (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121\u2013128","journal-title":"Lancet Oncol"},{"key":"3261_CR3","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K et al North-East Japan Study Group (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380\u20132388","journal-title":"N Engl J Med"},{"key":"3261_CR4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735\u2013742","journal-title":"Lancet Oncol"},{"key":"3261_CR5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R et al Spanish Lung Cancer Group in collaboration with Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie and Associazione Italiana Oncologia Toracica (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239\u2013246","journal-title":"Lancet Oncol"},{"key":"3261_CR6","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2005.04.9866","volume":"24","author":"M Ando","year":"2006","unstructured":"Ando M, Okamoto I, Yamamoto N et al (2006) Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 24:2549\u20132556","journal-title":"J Clin Oncol"},{"key":"3261_CR7","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1111\/cas.12550","volume":"105","author":"A Gemma","year":"2014","unstructured":"Gemma A, Kudoh S, Ando M et al (2014) Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10708 Japanese patients with non-small-cell lung cancer. Cancer Sci 105:1584\u20131590","journal-title":"Cancer Sci"},{"key":"3261_CR8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00280-009-1212-5","volume":"65","author":"T Fukui","year":"2010","unstructured":"Fukui T, Otani S, Hataishi R et al (2010) Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemother Pharmacol 65:803\u2013806","journal-title":"Cancer Chemother Pharmacol"},{"key":"3261_CR9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/JTO.0b013e3181dc39cd","volume":"5","author":"SC Chang","year":"2010","unstructured":"Chang SC, Chang CY, Chen CY et al (2010) Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia. J Thorac Oncol 5:1105\u20131106","journal-title":"J Thorac Oncol"},{"key":"3261_CR10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1159\/000332195","volume":"4","author":"Q Tian","year":"2011","unstructured":"Tian Q, Chen LA (2011) Erlotinib achieved partial response in a non-small cell lung cancer patient with gefitinib-induced interstitial lung disease. Case Rep Oncol 4:464\u2013466","journal-title":"Case Rep Oncol"},{"key":"3261_CR11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/JTO.0b013e318217b684","volume":"6","author":"JL Dallas","year":"2011","unstructured":"Dallas JL, Jantz MA, Lightsey JL et al (2011) Successful erlotinib rechallenge after erlotinib-induced interstitial lung disease. J Thorac Oncol 6:1142\u20131143","journal-title":"J Thorac Oncol"},{"key":"3261_CR12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.lungcan.2012.04.013","volume":"77","author":"Y Togashi","year":"2012","unstructured":"Togashi Y, Masago K, Hamatani Y et al (2012) Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature. Lung Cancer 77:464\u2013468","journal-title":"Lung Cancer"},{"key":"3261_CR13","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/JTO.0b013e3181d89ac2","volume":"5","author":"M Takeda","year":"2010","unstructured":"Takeda M, Okamoto I, Makimura C et al (2010) Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease. J Thorac Oncol 5:1103\u20131104","journal-title":"J Thorac Oncol"},{"key":"3261_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/rcr2.12","volume":"1","author":"N Arakawa","year":"2013","unstructured":"Arakawa N, Tsujita A, Saito N et al (2013) Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases. Respirol Case Rep 1:17\u201319","journal-title":"Respirol Case Rep"},{"key":"3261_CR15","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1093\/jjco\/hyt012","volume":"43","author":"S Nakamichi","year":"2013","unstructured":"Nakamichi S, Kubota K, Horinouchi H et al (2013) Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease. Jpn J Clin Oncol 43:422\u2013425","journal-title":"Jpn J Clin Oncol"},{"key":"3261_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/1752-1947-1-138","volume":"1","author":"K Takamochi","year":"2007","unstructured":"Takamochi K, Suzuki K, Bashar AH et al (2007) Readministration of gefitinib in a responder after treatment discontinuation due to gefinitib-related interstitial lung disease: a case report. J Med Case Rep 1:138. doi: 10.1186\/1752-1947-1-138","journal-title":"J Med Case Rep"},{"key":"3261_CR17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2169\/internalmedicine.47.0737","volume":"47","author":"M Suzuki","year":"2008","unstructured":"Suzuki M, Asahina H, Konishi J et al (2008) Recurrent gefitinib-induced interstitial lung disease. Intern Med 47:533\u2013536","journal-title":"Intern Med"},{"key":"3261_CR18","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1038\/sj.bjc.6602063","volume":"2","author":"P Camus","year":"2004","unstructured":"Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 2:S18\u2013S23","journal-title":"Br J Cancer"},{"key":"3261_CR19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","volume":"6","author":"M Schwaiblmair","year":"2012","unstructured":"Schwaiblmair M, Behr W, Haeckel T et al (2012) Drug induced interstitial lung disease. Open Respir Med J 6:63\u201374","journal-title":"Open Respir Med J"},{"key":"3261_CR20","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1038\/sj.bjc.6602064","volume":"91","author":"NL M\u00fcller","year":"2004","unstructured":"M\u00fcller NL, White DA, Jiang H et al (2004) Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer 91:S24\u2013S30","journal-title":"Br J Cancer"},{"key":"3261_CR21","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1378\/chest.07-0299","volume":"132","author":"R Hyzy","year":"2007","unstructured":"Hyzy R, Huang S, Myers J et al (2007) Acute exacerbation of idiopathic pulmonary fibrosis. Chest 132:1652\u20131658","journal-title":"Chest"},{"key":"3261_CR22","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1038\/sj.bjc.6602065","volume":"91","author":"T Higenbottam","year":"2004","unstructured":"Higenbottam T, Kuwano K, Nemery B et al (2004) Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 91:S31\u2013S37","journal-title":"Br J Cancer"},{"key":"3261_CR23","doi-asserted-by":"crossref","first-page":"4617","DOI":"10.1200\/JCO.2008.17.7162","volume":"26","author":"NSCLC Meta-Analyses","year":"2008","unstructured":"NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26:4617\u20134625","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3261-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-017-3261-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-017-3261-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T03:38:45Z","timestamp":1658720325000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-017-3261-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,3]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["3261"],"URL":"https:\/\/doi.org\/10.1007\/s00280-017-3261-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,3]]}}}